Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Ep 154: Climate Change and CV Health: From Heat Waves to Heart Risk
Added: 3 months ago
In this episode of Parallax, Dr Ankur Kalra speaks with Dr Sameed Khatana, Assistant Professor of Medicine at the University of Pennsylvania and clinical cardiologist at the Philadelphia VA Medical Center. Their conversation examines the growing connection between environmental factors and cardiovascular health.Dr Khatana explains why conditions like air quality and temperature represent… View more

CV Disease in Special Populations

Heart Failure
High-Dose Flu Vaccine Linked to Reduced Cardiovascular Hospitalisations in Older Adults
Added: 9 months ago Source:  Radcliffe Cardiology
A prespecified secondary analysis of the DANFLU-2 trial suggests that a high-dose inactivated influenza vaccine (HD-IIV) may offer greater protection against cardiovascular-related hospitalisations in older adults compared to a standard-dose vaccine (SD-IIV).¹˒² While the trial’s primary endpoint was not met, these exploratory findings point to a potential benefit in reducing the burden of… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Aniket S Rali
Research Area(s) / Expertise:
DrAniket Rali was born in Ahmedabad, Gujarat and moved to the US in 2003. He subsequently earned his double bachelor's degree in Molecular and Cellular Biology and Political Science from Vanderbilt University. He graduated with an MD from the University of Tennessee and completed his residency in Internal Medicine at Case Western University. Dr Rali completed a fellowship in cardiovascular… View more
Lars Kober
Research Area(s) / Expertise:
Dr Lars Kober is a professor of Cardiology and consultant from University of Copenhagen. Dr Kober serves as a member of the executive committee or steering committee in a number of large trials in heart failure and ischemic heart disease. The publication list encompasses more than 700 peer reviewed papers, and includes the 2015, 2016, 2017 Highly Cited Researchers listing by Thomson Reuters. Dr… View more
Navin K Kapur
Research Area(s) / Expertise: Job title: Associate Professor
Dr Navin K Kapur, MD, FAHA, FACC, FSCAI is Executive Director, The CardioVascular Center for Research and Innovation (CVCRI); Director, Acute Mechanical Circulatory Support Program; Director, Interventional Research Laboratories; Director of Cardiac Biology Research Center, Molecular Cardiology Research Institute (MCRI); Associate Professor, Tufts University School of Medicine. Dr Kapur's… View more
Tamas Alexy
Research Area(s) / Expertise: Job title: Assistant Professor of Medicine
Personal History Dr Tamas Alexy is a Cardiologist and Assistant Professor of Medicine based in Minneapolis, Minnesota. He speaks Hungarian and German.3, 5 Academic History Dr Alexy graduated Summa Cum Laude with his Medical Degree (2001) and earned his PhD in Clinical Cardiology (2005) from the University of Pecs Medical and Health Sciences Centre in Hungary.1, 2 He did his… View more
Research Area(s) / Expertise: Job title: Associate Director
John R Teerlink
Research Area(s) / Expertise: Job title: Director
Dr John R Teerlink is Director of the Heart Failure Program and of the Clinical Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center in San Francisco, California. Dr Teerlink graduated from Swarthmore College with Highest Honors in Comparative Religious Studies and Cellular Biology. After receiving his medical degree from Harvard Medical School, he completed an… View more
Research Area(s) / Expertise:

Heart Failure

Cardio-oncology

 Job title: Medical Director of Cardio-oncology
Dr Charles Porter is the Medical Director of Cardio-oncology atThe University of Kansas Hospital, Kansas City, US.He has been active in heart failure and transplant cardiology since 1984. He has afocus on preventing and managing heart failure in patients receiving Herceptin for breast cancer. He became the US Vice President of the International Cardio-oncology Society in 2010. He is the… View more
Beta-Blockers Cut MACE Risk Post-MI in Normal EF Patients
Added: 7 months ago Source:  Radcliffe Cardiology
The role of long-term beta-blocker therapy following a myocardial infarction (MI) in patients without heart failure remains a subject of clinical debate, particularly in the modern era of reperfusion and secondary prevention. The BETAMI–DANBLOCK trial sought to address this evidence gap by evaluating the efficacy of beta-blockers in this specific patient population.¹BETAMI–DANBLOCK was an open… View more

MI/ACS

Prevention & Chronic Conditions